Unify

Unify Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative conditions, with a primary focus on Huntington's disease. The company's lead program utilizes a small molecule approach designed to reduce the levels of mutant huntingtin protein, which is the underlying cause of the disease's progression. By targeting the genetic root of the disorder, Unify aims to provide a transformative treatment option for patients who currently have limited therapeutic choices. The company is currently in the pre-clinical stage, advancing its lead candidate toward regulatory filings and clinical trials.